20/20 Biolabs Inc (NASDAQ:AIDX) Shares Shorted: Short Interest Down 75.0% in October

20/20 Biolabs Inc (NASDAQ:AIDX) was the recipient of a significant drop in short interest in the month of October. As of October 15th, there was short interest totaling 11,270 shares, a drop of 75.0% from the September 30th total of 45,167 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average daily volume of 131,753 shares, the days-to-cover ratio is currently 0.1 days.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of 20/20 Biolabs from a “sell (e-)” rating to a “sell (e)” rating in a research note on Monday, August 3rd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $5.00.

20/20 Biolabs Stock Down 3.7%

Shares of 20/20 Biolabs stock traded down $0.01 during trading on Friday, reaching $0.22. 97,385 shares of the stock were exchanged, compared to its average volume of 399,543. The stock’s fifty day moving average is $0.43 and its 200 day moving average is $0.99. The firm has a market cap of $2.94 million and a price-to-earnings ratio of -0.41. 20/20 Biolabs has a 1 year low of $0.22 and a 1 year high of $50.00.

20/20 Biolabs (NASDAQ:AIDX) last announced its earnings results on Friday, August 14th. The company reported ($0.26) earnings per share for the quarter. The business had revenue of $0.73 million for the quarter.

About 20/20 Biolabs

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.